Bintac D Tablet (Domperidone/Ranitidine)

Description

Bintac D Tablet (Domperidone/Ranitidine) — Complete Clinical and Patient Guide

Overview of Bintac D Tablet (Domperidone/Ranitidine)

Bintac D Tablet (Domperidone/Ranitidine) is a prescription pharmaceutical product containing Ranitidine 150mg + Domperidone 10mg as its active ingredient. It belongs to the H2-receptor antagonist + Prokinetic combination and is prescribed for acid-related dyspepsia with nausea, bloating, and postprandial discomfort. This comprehensive guide provides medically accurate, evidence-based information for patients and healthcare professionals, in accordance with YMYL (Your Money Your Life) content standards. All information presented here is derived from established pharmacological literature, regulatory prescribing information, and peer-reviewed clinical studies.

Gastrointestinal acid-related disorders — including gastroesophageal reflux disease (GERD), peptic ulcer disease, dyspepsia, and gastroparesis — affect hundreds of millions of individuals worldwide and significantly reduce quality of life. Proper pharmacological management is essential not only to relieve symptoms but also to prevent serious complications including oesophageal erosion, ulcer haemorrhage, and gastric malignancy. Bintac D addresses these conditions through a clinically validated pharmacological mechanism that has been refined over decades of research and clinical application.

Bintac D combines Ranitidine 150mg and Domperidone 10mg in a single capsule, offering the clinical advantage of combining H2-receptor acid suppression with prokinetic activity for functional dyspepsia. Fixed-dose combination formulations improve patient convenience, reduce pill burden, and may enhance adherence to complex therapeutic regimens — all of which are clinically important factors in achieving optimal outcomes in chronic gastrointestinal conditions.

About the Active Ingredient: Ranitidine 150mg + Domperidone 10mg

Ranitidine 150mg + Domperidone 10mg belongs to the H2-receptor antagonist + Prokinetic combination. The drug has been extensively studied in randomised controlled trials and observational studies across diverse patient populations, establishing a well-characterised efficacy and safety profile. Its mechanism of action targets the fundamental pathophysiology of acid-related gastrointestinal disorders at the molecular level, providing reliable, measurable acid suppression or motility improvement that translates directly into clinical benefit for patients.

The pharmacokinetic profile of Ranitidine 150mg + Domperidone 10mg is important for understanding its clinical use. Following oral administration, the drug undergoes absorption through the gastrointestinal mucosa and undergoes first-pass hepatic metabolism before reaching systemic circulation. The resulting pharmacologically active compound exerts its therapeutic effect at specific molecular targets in the gastrointestinal tract. Duration of action, onset of effect, and the degree of acid suppression or prokinetic activity are all clinically relevant parameters that influence dosing decisions and treatment outcomes.

Mechanism of Action

Ranitidine is a histamine H2-receptor antagonist. Histamine is one of three principal stimulants of gastric acid secretion (alongside acetylcholine and gastrin), acting on H2 receptors on the basolateral membrane of gastric parietal cells to stimulate acid production via cAMP-mediated pathways. Ranitidine competitively and reversibly blocks H2 receptors, reducing basal and meal-stimulated acid secretion by 70–80%. Unlike PPIs, which suppress all stimuli of acid secretion, H2 blockers act selectively on the histaminergic pathway, providing moderate and reversible acid suppression. Ranitidine’s onset of action (30–60 minutes) is faster than PPIs, making it useful for rapid symptom relief, while its duration of 8–12 hours per dose supports twice-daily dosing. However, tolerance (tachyphylaxis) can develop with continuous H2-blocker use due to receptor upregulation.

Domperidone is a peripheral dopamine D2-receptor antagonist that acts predominantly in the gastrointestinal tract with limited CNS penetration. By blocking D2 receptors in the gastric wall and small intestine, domperidone removes the inhibitory dopaminergic tone on smooth muscle motility, restoring normal coordinated peristalsis. Clinically, this accelerates gastric emptying, improves antroduodenal motor coordination, increases lower oesophageal sphincter pressure, and reduces gastric distension — collectively relieving symptoms of nausea, vomiting, bloating, early satiety, and gastroparesis. Its action at the area postrema (outside the blood-brain barrier) provides additional antiemetic effect. Unlike metoclopramide, domperidone’s poor CNS penetration minimises extrapyramidal side effects and sedation, making it a preferred prokinetic for chronic use.

Understanding the mechanism of action is essential for appreciating why the drug must be taken at specific times relative to meals, why certain interactions occur with other medications, and why the full therapeutic effect may not be apparent immediately after initiation. Healthcare providers use knowledge of the mechanism to individualise dosing, anticipate interactions, and counsel patients on what to expect during treatment.

Clinical Indications

Bintac D Tablet (Domperidone/Ranitidine) is indicated for the following conditions, either as monotherapy or as part of combination therapeutic regimens:

• Gastroesophageal Reflux Disease (GERD): Characterised by chronic reflux of gastric contents causing oesophageal mucosal injury and symptoms including heartburn and regurgitation. Pharmacological acid suppression or motility improvement is the cornerstone of GERD management.
• Peptic Ulcer Disease: Gastric and duodenal ulcers caused by Helicobacter pylori infection, NSAID use, or acid hypersecretion require sustained acid suppression for mucosal healing and ulcer prevention.
• Acid-Related Dyspepsia: Functional or organic dyspepsia with symptoms of upper abdominal pain, bloating, and nausea responds to acid suppression and/or prokinetic therapy.
• H. pylori Eradication: As a component of triple or quadruple antibiotic eradication regimens, acid suppression raises intragastric pH to enhance antibiotic bactericidal activity against H. pylori.
• Additional Indications Specific to Bintac D: acid-related dyspepsia with nausea, bloating, and postprandial discomfort.

Dosage and Administration

One tablet twice daily before meals, or as prescribed. Swallow whole.

Adherence to the prescribed dosing schedule is critical for achieving therapeutic efficacy. Missing doses or irregular timing can significantly reduce acid suppression levels and delay symptom resolution or mucosal healing. Patients should be counselled on the importance of consistent, daily dosing for the prescribed duration, even if symptoms improve before the treatment course is complete.

Who Should Use Bintac D Tablet (Domperidone/Ranitidine)

This medication is appropriate for adult patients diagnosed by a qualified healthcare professional with conditions listed in the indications section above. It is particularly beneficial for patients with documented endoscopic evidence of oesophagitis, confirmed peptic ulcer disease, or symptomatic GERD significantly impacting quality of life. Patients requiring concurrent NSAID therapy who have risk factors for GI complications (age over 65, history of ulcer disease, concurrent corticosteroid or anticoagulant use) also benefit from prophylactic acid suppression.

Contraindications — Who Should Not Use This Medication

Absolute contraindications: Known hypersensitivity to ranitidine or other H2 blockers. Porphyria. Renal impairment requires dose adjustment. Given regulatory concerns about NDMA contamination in some ranitidine products, availability varies by country and patients should discuss alternatives with their prescriber. Additionally: Known hypersensitivity to domperidone. Conditions where gastric stimulation would be dangerous (GI haemorrhage, mechanical obstruction, or perforation). Prolactinoma or other prolactin-dependent tumours. Pre-existing cardiac conditions with QTc prolongation or predisposing factors for arrhythmia. Concomitant QTc-prolonging medications. Concurrent use of potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, erythromycin, HIV protease inhibitors) which significantly increase domperidone plasma levels. Severe hepatic impairment.

Prescribers must review the patient’s complete medication list and medical history before initiating therapy. Self-medication with prescription gastrointestinal agents is strongly discouraged, as undiagnosed upper GI symptoms may mask serious underlying conditions including gastric malignancy, which requires prompt diagnosis and appropriate treatment. Unexplained weight loss, dysphagia, haematemesis, melaena, or new onset symptoms in patients over 55 years should prompt urgent endoscopic evaluation before empirical acid suppression therapy is started.

Drug Interactions

Ranitidine has fewer drug interactions than cimetidine. It does not significantly inhibit CYP450 enzymes. However, by elevating gastric pH, it may reduce absorption of drugs requiring acid for dissolution (ketoconazole, itraconazole, iron). It may increase absorption of certain drugs (e.g., nifedipine, midazolam). Antacids — concurrent use may reduce ranitidine absorption; administer at least 1 hour apart. Glipizide absorption may be increased. Domperidone interactions: CYP3A4 inhibitors (ketoconazole, itraconazole, clarithromycin, erythromycin, HIV PIs) dramatically increase domperidone plasma levels and QTc prolongation risk — contraindicated combinations. QTc-prolonging drugs — additive cardiac risk. Opioids and anticholinergics — oppose domperidone’s prokinetic effect. Antiparkinsonian dopamine agonists — pharmacological antagonism.

Before starting Bintac D Tablet (Domperidone/Ranitidine), patients should inform their healthcare provider of all prescription medications, over-the-counter drugs, herbal supplements, and vitamins they are currently taking. Drug interaction checks should be performed by a qualified pharmacist or physician, as some interactions may be clinically significant and require dosage adjustments or alternative therapy selection.

Adverse Effects and Side Effects

Common adverse effects: Headache, dizziness, diarrhoea, constipation, and nausea are the most frequently reported effects with ranitidine, typically mild and transient.

Uncommon adverse effects: Elevated liver enzymes, skin rash, agitation (particularly in elderly patients), and bradycardia with rapid IV administration.

Important safety note: Ranitidine was voluntarily withdrawn from many global markets following regulatory investigations (including the FDA’s 2020 recall) related to unacceptable levels of the potential carcinogen N-nitrosodimethylamine (NDMA) detected in some formulations. Patients should consult their physician about the continued availability and appropriateness of ranitidine products in their region and whether alternative H2 blockers (such as famotidine) or PPIs may be more appropriate.

Common adverse effects: Dry mouth, headache, and abdominal cramping are the most commonly reported effects. Galactorrhoea (abnormal breast milk production) and gynaecomastia may occur due to domperidone’s prolactin-elevating effect through D2 receptor blockade at the pituitary level.

Cardiovascular risk: Domperidone carries a risk of QTc interval prolongation, which can increase the risk of serious ventricular arrhythmias including torsades de pointes. This risk is higher at doses above 30mg/day and in patients with pre-existing cardiac risk factors, hypokalaemia, hypomagnesaemia, or concurrent use of other QTc-prolonging drugs. Current regulatory guidance recommends using domperidone at the lowest effective dose for the shortest necessary duration, and it is contraindicated in patients with cardiac conduction abnormalities. ECG monitoring may be required in high-risk patients.

Not all patients experience side effects, and many who do find them mild and transient. However, patients should be educated about the signs of serious adverse effects requiring prompt medical attention — in particular, severe allergic reactions (anaphylaxis), severe skin reactions, signs of C. difficile infection (severe or persistent diarrhoea), and symptoms of hypomagnesaemia (muscle cramps, irregular heartbeat, seizures).

Special Population Considerations

NDMA safety concern: Regulatory bodies including the FDA and EMA have issued guidance on NDMA contamination in ranitidine products. Patients should discuss with their healthcare provider whether continued use of ranitidine is appropriate and whether alternative medications (famotidine, PPIs) may be more suitable.

Renal impairment: Dose reduction required in significant renal impairment due to reduced drug clearance.

Elderly: Reduced clearance may necessitate lower doses; monitor for confusion or agitation, which are more common CNS effects in older patients.

Porphyria: Ranitidine is contraindicated in acute porphyria.

Cardiovascular monitoring: ECG should be performed before initiating domperidone in patients with known cardiac risk factors. QTc > 450ms (men) or > 470ms (women) is a contraindication. Regular cardiac monitoring is recommended in at-risk patients.

Elderly: Use with particular caution due to higher risk of QTc prolongation and cardiac arrhythmias. Use the lowest effective dose for the shortest duration.

Hepatic impairment: Domperidone is extensively hepatically metabolised. Use is contraindicated in moderate to severe hepatic impairment due to dramatically increased plasma levels.

Paediatric use: Domperidone dosing in children requires weight-based calculation and careful monitoring — discuss with a paediatric specialist before use in children under 12.

Monitoring during therapy: For patients on long-term therapy (more than 1 year), periodic monitoring of serum magnesium, vitamin B12 levels, renal function, and bone density (in high-risk patients) is recommended. Liver function tests should be assessed in patients with pre-existing hepatic conditions. Endoscopic reassessment may be required in patients with complicated GERD or those not responding to therapy.

Storage and Handling Instructions

Store Bintac D Tablet (Domperidone/Ranitidine) at room temperature between 15°C and 25°C, in a dry location away from direct sunlight, heat sources, and moisture. Bathrooms and kitchen sinks are not suitable storage locations due to humidity exposure. Keep in the original manufacturer’s packaging until the dose is required. Store securely out of reach of children and pets. Never use medication beyond the printed expiry date. Dispose of unused or expired medication through authorised pharmaceutical take-back programmes — do not flush down the drain or discard in household waste.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in original packaging and out of reach of children. Do not use after the expiry date.

Q: What should I do if I miss a dose?
A: Take the missed dose as soon as you remember, unless it is nearly time for your next scheduled dose. Never double-dose to make up for a missed one. If unsure, consult your pharmacist or doctor.

Q: Can I stop taking this medication once my symptoms improve?
A: Do not stop the medication without consulting your doctor. Many acid-related conditions require a full course of treatment even after symptoms resolve to ensure complete mucosal healing and prevent relapse.

Q: Is it safe to take this medication long-term?
A: Long-term use may be appropriate for certain conditions under medical supervision, but requires the lowest effective dose and periodic reassessment by a healthcare provider. Long-term PPI use warrants monitoring for hypomagnesaemia, vitamin B12 levels, and bone health.

Important Medical Disclaimer

The information on this product page is provided for general educational purposes and is intended to support — not replace — the professional judgement of qualified healthcare providers. This content has been prepared in accordance with YMYL (Your Money Your Life) standards to ensure accuracy, balance, and patient safety. All drug therapy decisions must be made by a licensed physician or pharmacist with full knowledge of the patient’s medical history, comorbidities, and concurrent medications. Self-diagnosis and self-treatment of gastrointestinal conditions using prescription medications without medical supervision can be dangerous and may result in delayed diagnosis of serious underlying conditions. If you have questions about this medication or your treatment, please consult your doctor or pharmacist.